The Yellow Dialyzer Sign: An Unassuming Indicator of Occult Jaundice in Patients with End-stage Kidney Disease. A Case Report
Main Article Content
Keywords
Hyperbilirubinemia, Jaundice, Yellow dialyzer, Dialyzer discolouration, Lupus nephritis, Bilirubin
Abstract
In patients with end-stage renal disease (ESRD), diagnosing jaundice can be challenging because uremic skin changes and anuria may obscure classic signs such as scleral icterus and dark urine. We report a rare case in which discoloration of the hemodialysis circuit provided the first clue to occult hyperbilirubinemia. A 35-year-old woman with ESRD secondary to lupus nephritis presented for hemodialysis with features of uremia and fluid overload. Physical examination revealed no scleral icterus or skin discoloration. After a 2-hour session using a low-flux polysulfone dialyzer, a striking yellowish discoloration of the dialyzer membrane was noted. Laboratory evaluation, prompted by this observation, revealed marked unconjugated hyperbilirubinemia, elevated lactate dehydrogenase, low haptoglobin, and hemoglobinuria, confirming intravascular hemolysis complicating systemic lupus erythematosus. The yellow discoloration was attributed to the adsorption of bilirubin-albumin complexes onto the hollow fibers of the dialyzer membrane. The patient was treated with high-dose oral prednisolone for autoimmune hemolytic anemia associated with a lupus flare. Over three weeks and six subsequent dialysis sessions, hemolysis markers normalized, the yellow discoloration resolved, and her clinical condition improved significantly. Yellowish staining of the dialyzer membrane is an uncommon but important bedside sign of hyperbilirubinemia in patients undergoing dialysis. This extracorporeal indicator may reveal serious conditions such as intravascular hemolysis or hepatic dysfunction when conventional clinical signs are absent. Careful inspection of the dialysis circuit can facilitate early diagnosis, prompt treatment, and improved outcomes in this vulnerable population.
References
2.Kalakonda A, Jenkins BA, John S. Physiology, Bilirubin. 2022 Sep 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan
3.Hansen TWR, Wong RJ, Stevenson DK. Molecular Physiology and Pathophysiology of Bilirubin Handling by the Blood, Liver, Intestine, and Brain in the Newborn. Physiol Rev. 2020 Jul 1;100(3):1291-1346. doi: 10.1152/physrev.00004.2019.
4.Parikh, Rushang, Andrade paz, Hugo, Uppal, Nupur N, Sachdeva, Mala, A case of a yellow dialyzer in a hemodialysis patient. Abstract PO1196; American Society of Nephrology meeting 2020.
5.Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol. 2013 Oct 14;19(38):6398-407. doi: 10.3748/wjg.v19.i38.6398.
6.Dialysis, principles and treatment. The Pharmaceutical Journal. March, 2015. Available at https:// pharmaceutical-journal.com/article/ld/dialysis-principles-and-treatment-options. Last accessed on December 23rd, 2025
7.InformedHealth.org [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. In brief: How does dialysis work? 2018 Mar 8. Available from: https://www.ncbi.nlm.nih.gov/books/NBK492981/
8.Novokhodko A, Du N, Hao S, Wang Z, Shu Z, Ahmad S, Gao D. Predicting the Impact of Polysulfone Dialyzers and Binder Dialysate Flow Rate on Bilirubin Removal. Bioengineering. 2024; 11(12):1262. https://doi.org/10.3390/bioengineering11121262
9.Jeffries M, Hamadeh F, Aberle T, Glenn S, Kamen DL, Kelly JA, Reichlin M, Harley JB, Sawalha AH. Haemolytic anaemia in a multi-ethnic cohort of lupus patients: a clinical and serological perspective. Lupus. 2008 Aug;17(8):739-43. doi: 10.1177/0961203308090990.
10.Durán S, Apte M, Alarcón GS, Marion MC, Edberg JC, Kimberly RP, Zhang J, Langefeld CD, Vilá LM, Reveille JD; Lumina Study Group. Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort. Arthritis Rheum. 2008 Sep 15;59(9):1332-40. doi: 10.1002/art.24020.
11.Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med. 1996 Jun 24;156(12):1337-44.
12.Miranda-Hernández D, Cruz-Reyes C, Monsebaiz-Mora C, Gómez-Bañuelos E, Ángeles U, Jara LJ, Saavedra MÁ. Active haematological manifestations of systemic lupus erythematosus lupus are associated with a high rate of in-hospital mortality. Lupus. 2017 May;26(6):640-645. doi: 10.1177/0961203316672926.
